Trial Profile

Phase 1b Study of ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Jan 2022 Results (n=303) assessing dermatologic adverse events frequency and time to onset and characterize clinicopathologic features in a large cohort of PCa patients treated with apalutamide and recommend management strategies based on multidisciplinary (oncologist-dermatologist) experience from 7 clinical trials (NCT03009981, NCT01171898, NCT03141671, NCT03436654, NCT02903368, NCT02772588 and NCT02106507) and off-trial, published in the Journal of Urology.
29 Jun 2021 Status changed from active, no longer recruiting to completed.
28 Jan 2021 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com